Brevan Howard Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Brevan Howard Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$78.9K	Buy	+12,887	New	+$84.2K	﹤0.01%	2000
2026 Q1	–	Sell	-53,062	Closed	-$468K	–	2520
2025 Q4	$468K	Buy	+53,062	New	+$292K	0.01%	1148
2024 Q3	–	Sell	-31,256	Closed	-$177K	–	1463
2024 Q2	$177K	Buy	31,256 +12,968	+71%	+$67K	﹤0.01%	918
2024 Q1	$75.2K	Sell	18,288 -7,383	-29%	-$29.6K	﹤0.01%	919
2023 Q4	$108K	Buy	+25,671	New	+$104K	﹤0.01%	950

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brevan Howard Capital Management's VNDA Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Vanda Pharmaceuticals (VNDA) in Q2 2026: 12,887 shares worth $78.9K. The stake represents ﹤0.01% of the portfolio and ranks #2000 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in VNDA as recently as Q4 2025.

Brevan Howard Capital Management first reported a position in VNDA in Q4 2023 and has held it in 5 quarters since. The position peaked at $468K in Q4 2025. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

Brevan Howard Capital Management held 12,887 shares of Vanda Pharmaceuticals worth $78.9K as of Q2 2026.
Vanda Pharmaceuticals was a new Brevan Howard Capital Management position in Q2 2026.
Vanda Pharmaceuticals made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #2000 holding.
Brevan Howard Capital Management first reported a position in Vanda Pharmaceuticals in Q4 2023 and has held it in 5 quarters since.
Brevan Howard Capital Management's Vanda Pharmaceuticals position peaked at $468K in Q4 2025.
172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.